Overview

Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma

Status:
Not yet recruiting

Trial end date:
2023-08-20

Target enrollment:

Participant gender:

Summary

This is a single-arm phase II clinical trial to evaluate the initial efficacy and safety of pembrolizumab combined with axitinib as neoadjuvant therapy for locally advanced non-metastatic clear cell renal cell carcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

Tianjin Medical University Second Hospital

Treatments:

Axitinib
Pembrolizumab